Improved Transmucosal Delivery of Glimepiride via Unidirectional Release Buccal Film Loaded With Vitamin E TPGS-Based Nanocarrier

Basahih, Tahani S; Alamoudi, Abdullah A.; El-Say, Khalid M.; Alhakamy, Nabil A.; Ahmed, Osama A. A.

doi:10.1177/1559325820945164

Cited by 13 publications

(7 citation statements)

References 54 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The formulated films were subjected to a thickness test, using a digital micrometer (Mitutoyo, IP65, Waltham, MA, USA). Thickness from three different locations from each strip was determined and their average thickness was calculated [ 33 ].…”

Section: Methodsmentioning

confidence: 99%

The Development of Eletriptan Hydrobromide Immediate Release Buccal Films Using Central Composite Rotatable Design: An In Vivo and In Vitro Approach

et al. 2022

View full text Add to dashboard Cite

The objective is to develop immediate release buccal films of Eletriptan Hydrobromide (EHBR) using hydroxypropyl methylcellulose (HPMC) E5. The buccal films have the ability to disintegrate rapidly and provide both systemic and local effects. The solvent casting method was employed to prepare the films and the central composite rotatable design (CCRD) model was used for film optimization. All the formulated films were characterized for physicochemical evaluation (Fourier transform infrared spectroscopy (FTIR), X-ray Diffraction (XRD), differential scanning calorimetry (DSC), and Scanning electron microscopy (SEM), in in-vitro, ex-vivo, and in-vivo drug release. The fabricated films were transparent, colorless, and evenly distributed. The FTIR spectra showed no chemical interaction between the drug and excipients. In in-vitro analysis, the film has the highest% drug release (102.61 ± 1.13), while a maximum of 92.87 ± 0.87% drug was diffused across the cellulose membrane having a pore size of 0.45 µm. In the ex-vivo study, drug diffusion across the goat mucosa was performed and 80.9% of the drug was released in 30 min. In-vivo results depict a mean half-life (t½) of 4.54 ± 0.18 h and a Cmax of 128 ± 0.87 (ng/mL); Tmax was achieved in 1 h. Furthermore, instability and histopathological studies buccal films were proven to be safe and act as an effective dosage form. In a nutshell, optimized and safe instant release EHBR buccal films were prepared that have the tendency to provide effect effectively.

show abstract

Section: Methodsmentioning

confidence: 99%

The Development of Eletriptan Hydrobromide Immediate Release Buccal Films Using Central Composite Rotatable Design: An In Vivo and In Vitro Approach

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The AVA ex vivo permeation study was conducted utilizing a USP dissolution apparatus (Pharma test, Hainburg, Germany) as previously described [ 30 ]. Freshly isolated rat skin (male Wistar rats (200–250 g weight) was used as a membrane.…”

Section: Methodsmentioning

confidence: 99%

“…A raw FITC-loaded transdermal film was used as a control. The prepared films were mounted on skin patches and investigated using an automated Franz diffusion apparatus [ 30 ]. A skin patch of each cell was taken out after 0.50, 3, and 6 h, then fixed in formaldehyde solution, sectioned by a microtome from paraffin wax skin samples, and investigated under the microscope.…”

Section: Methodsmentioning

confidence: 99%

Investigating the Potential of Transdermal Delivery of Avanafil Using Vitamin E-TPGS Based Mixed Micelles Loaded Films

2021

Self Cite

View full text Add to dashboard Cite

To avoid the first-pass metabolism of avanafil (AVA) and its altered absorption in the presence of food after oral administration, this study aimed to investigate the potential of TPGS-based mixed micelle (MM)-loaded film for transdermal delivery and the enhancement of bioavailability. A Box–Behnken design was employed to optimize the permeation behavior of AVA from the transdermal film across the skin. The variables were the hydrophile-lipophile balance (HLB) of the surfactant (X1), the concentration of mixed micelles (MMs) in the film (X2), and the concentration of the permeation enhancer (X3). The initial permeation of AVA after 1 h (Y1), and the cumulative permeation of AVA after 24 h (Y2) were the dependent variables. Ex vivo studies were carried out on freshly isolated rat skin to investigate the drug’s permeation potential and results were visualized using a fluorescence laser microscope. Moreover, the pharmacokinetic behavior after a single application on male Wistar rats, in comparison with films loaded with raw AVA, was evaluated. The results showed that the optimum factor levels were 9.4% for the HLB of the surfactant used, and 5.12% MMs and 2.99% penetration enhancer in the film. Imaging with a fluorescence laser microscope indicated the ability of the optimized film to deliver the payload to deeper skin layers. Furthermore, optimized AVA-loaded TPGS-micelles film showed a significant increase (p < 0.05) in the Cmax of AVA and the area under the AVA plasma curve (approximately three-fold). The optimized AVA-loaded TPGS-MM film thus represents a successful delivery system for enhancing the bioavailability of AVA.

show abstract

“…The boosted one direction release of GMD transmucosal film was about 93.9% in 6 h compared to 60.41% of GMD release from the standard GMD film. This conclusion was established by its property to transport the GMD across the buccal mucosa, thereby showed by the ferocity of fluorescence with the fluorescence-labeled upgraded formulation [67]. Chlorzoxazone was modified by solid dispersion technique to refine its solubility and then incorporated it in buccal film.…”

Section: Haju Et Almentioning

confidence: 99%

Buccal Film: A Novel Approach for Oral Mucosal Drug Delivery System

Haju¹,

Yadav²,

BAIG³

et al. 2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Buccal drug delivery especially refers to the delivery of drugs through the buccal mucosal membrane lining of the oral cavity. For geriatric and pediatric patients who undergo difficulties in swallowing conventional oral solid dosage forms, the buccal film is a better alternative. The buccal film is appropriate for the drugs which experience high first-pass metabolism and is used for enhancing bioavailability with reducing dosing frequency to mouth plasma peak levels, which thus limit side-effects and make it cost-effective. It enhances the efficacy of API in the oral cavity after the contact with less saliva as contrasted to tablets, without chewing and no need for water for administration. This review briefly describes the advantages and limitations of buccal film, an anatomical structure of oral mucosa, highlighting the mechanisms of drug permeation, formulation technologies, methodology in evaluating buccal film, and recent advances of the buccal film as a tool for drug delivery for various treatments.

show abstract

Improved Transmucosal Delivery of Glimepiride via Unidirectional Release Buccal Film Loaded With Vitamin E TPGS-Based Nanocarrier

Cited by 13 publications

References 54 publications

The Development of Eletriptan Hydrobromide Immediate Release Buccal Films Using Central Composite Rotatable Design: An In Vivo and In Vitro Approach

The Development of Eletriptan Hydrobromide Immediate Release Buccal Films Using Central Composite Rotatable Design: An In Vivo and In Vitro Approach

Investigating the Potential of Transdermal Delivery of Avanafil Using Vitamin E-TPGS Based Mixed Micelles Loaded Films

Buccal Film: A Novel Approach for Oral Mucosal Drug Delivery System

Contact Info

Product

Resources

About